Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Melanoma

Interventions

DRUG

Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

MS-275, 3 mg on Days 1 and 15 of a 4-week cycle

DRUG

Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle